1. Home
  2. INCY
  3. INCY News

Latest Incyte Corp. (INCY) News on February 5, 2025

Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
INCY

Zacks

a day ago

Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

Incyte (INCY) Earnings Expected to Grow: Should You Buy?
INCY

Zacks

2 days ago

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Exploring High Growth Tech Stocks In January 2025
INCY

Simply Wall St.

6 days ago

Exploring High Growth Tech Stocks In January 2025

INCY

MT Newswires

14 days ago

RBC Adjusts Price Target on Incyte to $70 From $75, Maintains Sector Perform Rating

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY

Business Wire

15 days ago

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY

Zacks

16 days ago

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

INCY

MT Newswires

20 days ago

Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
INCY

PR Newswire

21 days ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

JP Morgan 2025: Incyte expects period of ‘defining catalysts’
INCY

Pharmaceutical Technology

21 days ago

JP Morgan 2025: Incyte expects period of ‘defining catalysts’

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
INCY

Zacks

21 days ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

5 Biotech Stocks Worth Adding to Your Portfolio in 2025
INCY

Zacks

22 days ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
INCY

Zacks

23 days ago

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
INCY

Business Wire

23 days ago

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

INCY vs. VRTX: Which Stock Is the Better Value Option?
INCY

Zacks

a month ago

INCY vs. VRTX: Which Stock Is the Better Value Option?

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

a month ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

a month ago

RBC Lifts Price Target on Incyte to $75 From $74, Keeps Sector Perform Rating

Exploring Three High Growth Tech Stocks in the United States
INCY

Simply Wall St.

a month ago

Exploring Three High Growth Tech Stocks in the United States

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
INCY

Zacks

a month ago

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

Incyte price target raised to $70 from $68 at Wells Fargo
INCY

TipRanks

2 months ago

Incyte price target raised to $70 from $68 at Wells Fargo

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
INCY

Zacks

2 months ago

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

INCY

MT Newswires

2 months ago

Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating

INCY

MT Newswires

2 months ago

UBS Initiates Coverage on Incyte With Neutral Rating, $77 Price Target

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

2 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

2 months ago

Leerink Adjusts Price Target on Incyte to $100 From $87, Maintains Outperform Rating

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma
INCY

Clinical Trials Arena

2 months ago

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma
INCY

Clinical Trials Arena

2 months ago

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
INCY

Zacks

2 months ago

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

INCY

MT Newswires

2 months ago

Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY

Business Wire

2 months ago

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

INCY

Morningstar Research

2 months ago

Analyst Report: Incyte Corporation

Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
INCY

Zacks

2 months ago

Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals

EXEL or INCY: Which Is the Better Value Stock Right Now?
INCY

Zacks

2 months ago

EXEL or INCY: Which Is the Better Value Stock Right Now?

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
INCY

Business Wire

2 months ago

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

2 months ago

Incyte Insider Sold Shares Worth $455,544, According to a Recent SEC Filing

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
INCY

Zacks

2 months ago

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
INCY

Zacks

2 months ago

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Exploring 3 High Growth Tech Stocks in the United States
INCY

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks in the United States

Incyte Announces Updated Presentation Time for Upcoming Investor Conference
INCY

Business Wire

2 months ago

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
INCY

Business Wire

2 months ago

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

INCY

MT Newswires

2 months ago

TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating

Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
INCY

Insider Monkey

2 months ago

Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
INCY

Zacks

2 months ago

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
INCY

MT Newswires

3 months ago

Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict

INCY

MT Newswires

3 months ago

Equity Markets Close Mixed Ahead of Nvidia Earnings

S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
INCY

Investopedia

3 months ago

S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing

INCY

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline

INCY

MT Newswires

3 months ago

Top Midday Decliners

Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
INCY

MT Newswires

3 months ago

Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict

INCY

MT Newswires

3 months ago

Incyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
INCY

Zacks

3 months ago

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
INCY

Investor's Business Daily

3 months ago

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

INCY

MT Newswires

3 months ago

RBC Cuts Price Target on Incyte to $74 From $80, Keeps Sector Perform Rating

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
INCY

Business Wire

3 months ago

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?
INCY

Insider Monkey

3 months ago

Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
INCY

Insider Monkey

3 months ago

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

3 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

3 months ago

RBC Raises Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating

INCY

MT Newswires

3 months ago

RBC Capital Adjusts Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating

INCY

MT Newswires

3 months ago

Incyte Insider Sold Shares Worth $293,210, According to a Recent SEC Filing

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

3 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bank of America Turns Bullish on These 2 Lesser-Known Stocks
INCY

TipRanks

3 months ago

Bank of America Turns Bullish on These 2 Lesser-Known Stocks

Syndax agrees funding with Royalty Pharma for Niktimvo US sales
INCY

Pharmaceutical Technology

3 months ago

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

BMRN vs. INCY: Which Stock Is the Better Value Option?
INCY

Zacks

3 months ago

BMRN vs. INCY: Which Stock Is the Better Value Option?

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
INCY

Benzinga

3 months ago

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock

INCY

MT Newswires

3 months ago

Deutsche Bank Adjusts Price Target on Incyte to $70 From $61

INCY

MT Newswires

3 months ago

Morgan Stanley Adjusts Price Target on Incyte to $69 From $64

INCY

MT Newswires

3 months ago

JPMorgan Adjusts Price Target on Incyte to $71 From $65

INCY

MT Newswires

3 months ago

Goldman Sachs Adjusts Price Target on Incyte to $70 From $63

INCY

MT Newswires

3 months ago

Oppenheimer Adjusts Price Target on Incyte to $82 From $81

INCY

MT Newswires

3 months ago

Leerink Partners Adjusts Price Target on Incyte to $87 From $85

INCY

MT Newswires

3 months ago

Piper Sandler Adjusts Price Target on Incyte to $82 From $80

INCY

MT Newswires

3 months ago

Argus Adjusts Price Target on Incyte to $80 From $75

Incyte to Present at Upcoming Investor Conferences
INCY

Business Wire

3 months ago

Incyte to Present at Upcoming Investor Conferences

INCY

Argus Research

3 months ago

Analyst Report: Incyte Corp.

Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
INCY

Simply Wall St.

3 months ago

Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

INCY

Argus Research

3 months ago

Market Digest: NVS, BRO, ECL, F, GLW, INCY, TMUS, PFE, PKG, RSG

INCY

MT Newswires

3 months ago

BofA Upgrades Incyte to Buy From Neutral, Adjusts Price Target to $90 From $68

Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
INCY

GuruFocus.com

3 months ago

Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

INCY

Thomson Reuters StreetEvents

3 months ago

Q3 2024 Incyte Corp Earnings Call

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
INCY

Investor's Business Daily

3 months ago

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

INCY

MT Newswires

3 months ago

Stifel Raises Incyte's Price Target to $75 From $73

INCY

MT Newswires

3 months ago

Jefferies Raises Incyte's Price Target to $84 From $81

INCY

MT Newswires

3 months ago

RBC Raises Incyte's Price Target to $72 From $67

INCY

MT Newswires

3 months ago

BofA Securities Upgrades Incyte to Buy From Neutral, $90 Price Target

Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted
INCY

GuruFocus.com

3 months ago

Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted

INCY

MT Newswires

3 months ago

Wells Fargo Adjusts Price Target on Incyte to $68 From $62, Maintains Equalweight Rating

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
INCY

Benzinga

3 months ago

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura

INCY

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

Incyte (INCY) Q3 Earnings Miss Estimates
INCY

Zacks

3 months ago

Incyte (INCY) Q3 Earnings Miss Estimates

INCY

MT Newswires

3 months ago

Incyte Q3 Non-GAAP Net Income Falls, Revenue Rises

INCY

Associated Press Finance

3 months ago

Incyte: Q3 Earnings Snapshot

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY

Business Wire

3 months ago

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

INCY

MT Newswires

3 months ago

Leerink Partners Adjusts Price Target on Incyte to $85 From $84, Maintains Outperform Rating

Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
INCY

Business Wire

3 months ago

Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List

INCY

MT Newswires

3 months ago

JPMorgan Chase Adjusts Price Target on Incyte to $65 From $61

Share on Social Networks: